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Despite dramatic advances in the molecular patho-
genesis of disease, translation of basic biomedical 
research into safe and effective clinical applications 
remains a slow, expensive, and failure-prone endeavor.
Francis S. Collins1
The global burden of stroke on patients, their relatives, health systems, and the economies that support them is 
tremendous. In an unprecedented move, the World Health 
Organization (WHO) and the United Nations have responded 
to this challenge by declaring the fight against stroke a top pri-
ority in their drive to prevent and to control noncommunicable 
diseases.2 Indeed, great progress has been made in our under-
standing of stroke pathophysiology. This has led to the devel-
opment of thrombolysis, a highly efficient therapy for a subset 
of patients with acute ischemic stroke. We came to realize that 
the responses of brain tissue to substrate deprivation are com-
plex, and that not only neurons need to be considered but also 
glial and vascular cells, as well as local or blood-derived cells 
of the immune system.3–5 We now know that ischemia triggers 
a multitude of endogenous protective mechanisms in the brain 
which help to contain the ischemic lesion evolution and pro-
tect the brain from further damage.6 The brain has a tremen-
dous capacity to overcome functional deficits, and as we begin 
to understand how brain plasticity works, we are actually find-
ing evidence for tissue repair.7 We are also beginning to appre-
ciate the interaction between the ischemic brain and the other 
organ systems, such as the immune system,8 the cardiovascu-
lar system, or systemic metabolism, a multidirectional signal-
ing with tremendous impact on the outcome of patients with 
stroke.9 Taken together, research during the past few decades 
has suggested numerous targets for therapeutic intervention 
to restore perfusion, block mechanisms of damage, or induce 
endogenous mechanisms of protection, intercept deleterious 
signaling to other organs, or to even foster plasticity or repair 
to recover lost function. Treatment approaches based on this 
understanding have demonstrated efficacy in a variety of pre-
clinical models of the disease.
However, associated clinical trials have been unable to 
translate most of these advances into drugs with a clear benefit 
in patients. Developing new drug treatments for human dis-
ease is challenging in any field, and the number of new drugs 
coming to market continues to fall. Although large numbers 
of novel treatment strategies are developed in laboratories 
each year and show beneficial effects in animal models, very 
few are ultimately proven to be effective in patients.10,11 The 
stroke field has been particularly affected by the failure to 
translate drug efficacy in stroke from animal studies to clini-
cal trials.12
The reasons underlying this translational roadblock13,14 
are currently being discussed intensely by stroke researchers 
and in industry and funding agencies worldwide. They are all 
struggling to develop strategies to overcome the roadblocks 
impeding the development of effective therapies. For example, 
the European Commission invited a group of European 
stroke experts to provide research priorities for attacking this 
translational roadblock.15 More recently, basic and clinical 
stroke researchers from North America, Europe, and the 
Asia-Pacific regions convened in 2 workshops (Barcelona, 
Spain, May 2011 and Potsdam, Germany, May 2012). The 
need for international collaboration in cerebrovascular 
research and therapeutics was also discussed at the meeting 
of the American Association for the Advancement of Science 
(Boston, February 2013). Likewise, the Stroke Progress 
Review Group of the National Institutes of Health (NIH)/
National Institute of Neurological Disorders and Stroke 
(NINDS), recently conducted a 10-year review of the state 
of stroke research16 and set priorities to shape future NINDS 
programs and policies focusing on the improvement of bench 
to beside translation and stressing the importance of research 
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cooperation and research networks. We wish to summarize 
the background for such cooperation and outline a proposal 
that might be a first step toward accelerating progress in 
translational stroke research.
Stroke: A Global Challenge
Worldwide >15 million strokes and 6 million stroke deaths 
occur per year, and 55 million survivors are experiencing the 
consequences of a stroke. The costs of stroke are substantial. 
After adjusting for inflation, it has been estimated that they 
range in the developed world from US$266 billion to US$1038 
billion each year.17 The WHO forecasts a global doubling of 
these figures by 2030 as the world population ages.18 Although 
stroke engenders a massive family and societal burden, we 
unfortunately have few effective therapies. Thrombolysis, 
because of its short time window, diagnostic requirements, 
and contraindications, can only benefit a small percentage of 
stroke patients.19 Stroke units have proven to produce reduc-
tions in mortality, institutionalized care, or dependency, but 
effect sizes and availability are limited.20 This paucity of ther-
apeutic options persists, despite intensive research efforts to 
develop new effective therapies.
The Problem: Failure to Translate
The translation of animal model research to the stroke patient 
is best exemplified by the success of reperfusion strategies. 
There is a wealth of large and small animal experience, and 
a growing body of work on vascular processes in the central 
nervous system. It is clear that the location and the extent of 
ischemic injury begin within the first moments of the vascular 
occlusion. However, we only partially understand the exact 
events that ensue from occlusion of a major brain-supplying 
artery, the brain’s attempts to recover from the insult, or the 
complex interplay of brain, cardiovascular, and immune sys-
tem before stroke hits and in its wake. A deeper understand-
ing of these mechanisms is a prerequisite for the development 
of novel treatment strategies that benefit patients, in whom 
comorbidities and age further complicate pathobiology.
In addition, there is a growing body of quantitative evi-
dence that preclinical stroke research, just as in other areas of 
biomedicine, has been confounded by quality problems and 
negative publication bias.11,21,22 Our experimental paradigms 
are designed to show large treatment effects, and although sta-
tistically efficient, they may be clinically less relevant. In view 
of the difficulties in developing novel and effective therapies 
for this common and disabling disorder, there is a clear need 
to rethink the paradigms and dogmas of this research field. 
Worldwide, researchers and funding agencies have been 
analyzing potential causes for the translational roadblock. 
Independently, several common themes have evolved from 
these discussions (Table 1). One view is that the complexity 
of the stroke research problem cannot be solved on a local or 
a national level, and that a transnational effort may be needed 
to bundle preclinical research capacity and link it to the clini-
cal realm.
Multiple Opportunities
Most experts agree that there is no fundamental reason to 
believe that reperfusion and treatment in stroke units need to 
remain the only effective treatment options for patients with 
ischemic stroke. This optimism is fueled by the observation 
that numerous examples of preclinical research have paral-
lel examples of improved outcomes in the clinic (Table 2). 
In addition, opportunities are available for multidisciplinary 
strategies to generate new knowledge on prevention, mech-
anisms of injury, plasticity, and repair. The Stroke Progress 
Review Group has identified and prioritized many scientific 
research opportunities and medical needs in stroke prevention, 
treatment, and recovery research.16
Prevention
Technological advances in high throughput genotyping will 
allow major breakthroughs in the elucidation of the genetics 
of cerebrovascular risk factors, in particular through Genome-
Wide Association Studies46 and exome sequence analysis.47 
An important focus will be the prevention of cerebral small 
vessel disease, a major contributor to age-related cognitive 
impairment, and a range of agents that might reduce damage 
to cerebral small vessels in high-risk populations are currently 
undergoing preclinical testing.48
Treatment
Reperfusion via intravenous thrombolysis has helped to 
establish the time is brain concept in acute stroke treatment 
and accomplish major improvements in treatment infrastruc-
ture, culminating in the concept of mobile stroke units.49 
These studies have paved the way for testing hyperacute 
(golden hour) treatments, including some previously tested 
agents, which may have been effective had they been initi-
ated earlier than they were in prior trials. Recent research on 
Table 1. Lost in Translation—Some Potential Reasons Why Clinical Stroke Trials Were Unable to Replicate Bench Findings
Complexity of ischemic pathophysiology underestimated
Low quality of preclinical studies, underpowered, effect sizes overestimated, results not robust (low internal validity)
Stroke models do not match with patient characteristics (age, sex, comorbidities, polypharmacology; low external validity)
Negative publication bias (particularly in preclinical research)
Heterogeneity of stroke patients, therapies not matched to individual pathophysiology
Super systemic effects (on immune, cardiovascular system, etc) attributable to a substantial fraction of stroke morbidity and mortality, but little understood and 
under-researched
Timing of therapy wrong or clinically irrelevant, clinical trial design not matched to preclinical findings
Significant species differences
 by guest on May 27, 2013http://stroke.ahajournals.org/Downloaded from 
1756  Stroke  June 2013
endogenous brain protective strategies has led to the discov-
ery of a number of promising treatment strategies that boost 
such evolutionarily conserved mechanisms.6 Although clini-
cal beneficial neuroprotection has been elusive so far, brain 
protection in combination with reperfusion seems logical and 
carries the potential to increase the benefit of reperfusion by 
blocking some of its deleterious effects.50 In addition, the 
efficacy of recanalization and reperfusion may be improved, 
either by the use of alternative thrombolytics51 or by mechani-
cal devices.52
Recovery and Rehabilitation
The brain can recover function after injury, at least 
partially. Only recently we have started to understand the 
mechanisms of this remarkable plasticity and regeneration. 
This has led to pharmacological strategies to foster recovery, 
pharmacologically, via cell therapy, rehabilitation measures, 
stimulation devices, or robotics.53 For example, there is strong 
evidence that transcranial electric stimulation, in particular, 
when combined with behavioral practice has beneficial effects 
on stroke rehabilitation outcomes.54 Likewise, there seem 
to be exciting opportunities for neuromodulation of stroke 
recovery through emerging technologies, such as MR-guided 
focused ultrasound. Biotechnological developments may 
provide new avenues for fostering endogenous recovery, 
whereas nanotechnology drug delivery approaches offer novel 
possibilities for stroke treatment. The remarkable advances in 
cell therapy for stroke underscore the firm role of this strategy 
in future research endeavors.
Further opportunities to develop successful strategies to 
prevent and to treat stroke successfully are emerging from 
research on the interplay of the various cellular elements of 
the brain, the neurovascular unit.55 In a paradigmatic shift, 
the field has realized that a neurocentric view oversimplifies 
stroke pathophysiology. Since then it has become clear that a 
complex interaction of endothelial cells, astrocytes, microglia, 
pericytes, inflammatory cells from the blood, etc, determines 
the fate of brain tissue after stroke. This research has now 
exposed numerous new targets for treatment.56
Another transformative area was the investigation of the 
complex interaction of the injured brain after stroke with 
peripheral organs,57 in particular, the immune system.58 
Complications are a highly important contributor to the 
morbidity and mortality of stroke, and also a major problem for 
recovery.59 We are now starting to understand the underlying 
mechanisms (eg, stroke-induced immunodepression), which 
increases susceptibility to infection,60) and promising therapies 
are being developed. It is very likely that ongoing research 
on the interaction of the brain after stroke with systemic 
metabolism, the cardiovascular system, the liver, the gut 
microbiome, etc, will lead us to further therapeutic targets to 
improve stroke outcome.
All these approaches will be greatly helped by the 
advances in the identification and validation of biomarkers 
(blood, imaging61,62) for most relevant stroke subtypes in 
combination with (epi)genetic and premorbidity phenotyp-
ing to predict disease pathophysiology. The ultimate goal 
of these promising developments is to use transcriptomics, 
proteomics, as well as immunology, and noninvasive brain 
imaging (computed tomography, MR, single-photon emis-
sion computed tomography, positron emission tomogra-
phy) to establish diagnostic fingerprints of disease-specific 
markers to stratify patients in a time and pathophysiological 
context-dependent manner.
Table 2. Found in Translation—Stroke Models Predict or Parallel Clinical Phenotypes
Pathophysiological concepts The penumbra concept was developed and refined in animal models of 
cerebral ischemia, and has proven clinical usefulness
Astrup et al23
Thrombolysis is the only pharmacological treatment of acute ischemic 
stroke of proven efficacy, is equally efficacious in embolic models of 
stroke
Zivin et al,24 The National Institute of Neurological 
Disorders and Stroke rtPA Stroke Study Group25
Spreading depolarizations and spreading ischemia, first described in 
animal models, occur in humans and correlate with spread of lesion
Dreier26
Treatments Identical time window for rtPA thromobolysis in rodents and humans Quartermain et al,27 Zhu et al,28 Lees et al29
Hypothermia, a concept originating from and refined in animal models 
of cerebral ischemia, has entered clinical guidelines to protect the brain 
after cardiac arrest
Rosomoff,30 hypothermia after Cardiac Arrest Study 
Group,31 Bernard et al32
In mouse and man: increased risk of hemorrhage and BBB disruption in 
erythropoietin/tPA treatment
Ehrenreich et al,33 Zechariah et al34
Mouse studies predict outcome of human GPIIb/IIIa receptor  
antagonist trial
Kleinschnitz et al,35 Adams et al36
In mouse and man: statin use during stroke is protective, withdrawal is 
potentially harmful
Gertz et al,37 Flint et al38
In mouse and man: clinical deterioration after treatment with xenogenic 
intercellular adhesion molecule-1 antibody (Enlimomab)
Furuya et al39; Enlimomab Acute Stroke Trial 
Investigators40
Complications Weight loss and sarkopenia after stroke: body weight changes after 
experimental stroke parallel those in humans
Jönsson et al,41 Scherbakov et al42
Super systemic effects of stroke in animal models are predictive for 
those effects in humans (eg, immune system and infection)
Prass et al,43 Urra et al,44 Vogelgesang et al45
BBB indicates blood brain barrier; rtPa, recombinant tissue-type plasminogen activator; and tPA, tissue-type plasminogen activator.
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In all these areas, we are only beginning to understand the 
pathobiological mechanisms, and it is clear that further pre-
clinical research is necessary. Agreement exists that modeling of 
cerebrovascular disease should include advanced age and comor-
bidities typical of the human disease, such as diabetes mellitus 
and hypertension, as well as environmental factors (eg, Fisher et 
al63). However, because of the overwhelming costs and technical 
challenges of modeling stroke in aged comorbid animals, most 
studies have used healthy young animals. This could be over-
come by combining the expertise and availability of models and 
confounders in a network of international experts, and by provid-
ing incentives for crossvalidation within the network.
Thus, numerous possibilities for transnational research 
cooperation exist that address the problems of fragmentation, 
limited resources, and the need for multidisciplinary training 
of new stroke scientists.
Following the example of clinical medicine, in which mul-
tinational consortia conduct clinical trials, and some highly 
effective international cooperation in the preclinical realm (see 
below), we propose the development of multinational stroke 
research initiatives. Sharing data and biomaterial in preclini-
cal stroke research, as well as combining research excellence 
to elucidate novel pathophysiological concepts, and consen-
sus on therapeutic targets, could accelerate translation to clini-
cal trials. This could lead to the establishment of international 
quality standards with crossvalidation and reproduction of 
results before decision making on clinical development.64,65
Successful Examples of International  
Research Collaboration
Research is an international effort and scientists are already col-
laborating on many individual cerebrovascular research proj-
ects. However, scaling up collaborations to the level required 
to generate the resources and synergies needed requires a struc-
tured process. Ideally, such a process can be simultaneously 
executed by groups of researchers and clinicians (bottom-up) 
and by funding agencies and scientific societies (top-down) 
in a coordinated way. An example for a successful bottom up 
interaction of international scientists is the development of 
thrombolysis for stroke in the 1980s–2000s, which in its course 
also led to an improvement in clinical stroke trial expertise. 
However, a top example of a highly successful structured inter-
national research collaboration in biomedicine, is the decipher-
ing of the human genome. We may also learn how to organize 
and govern multinational research from ongoing international 
collaborations, such as those in genetics. Triggered by rapid 
methodological advances in genotyping large numbers of indi-
viduals, successful approaches to project selection, data depo-
sition and distribution, collaborative analysis, publication and 
protection of intellectual property claims on a large, interna-
tional scale were recently developed (eg, GAIN Collaborative 
Research Group66), many of which can serve as templates 
for other fields. Extreme but instructive examples from out-
side medicine include research collaborations in physics that 
are focused on experiments using expensive equipment (par-
ticle accelerators and detectors, eg, European Organization for 
Nuclear Research CERN: http://www.cern.org) or on research 
on matter under extreme conditions of temperature, pressure, or 
density (eg, Extreme Matter Institute EMMI: http://www.gsi.
de/emmi). Apparently, the physics community has established 
a culture of collaboration that makes possible such highly suc-
cessful large-scale initiatives and that pervades their entire 
research operation, including their publication practice (eg, 
their archive for electronic preprints of scientific papers arXiv: 
http://www.arxiv.org). We would hope that stroke pathophysiol-
ogy is easier to decipher than the fundamental physical laws of 
nature, but we suggest that many lessons can be learned from 
these other examples of international scientific cooperation, 
in particular, with respect to organization, upscaling, and gov-
ernance. Importantly, a strong foundation for development of 
international stroke research collaborations has been laid by 2 
large preclinical research consortia that are currently demon-
strating the benefits of sharing results, distributing tasks, and 
bundling expertise in stroke research. These are the European 
Stroke Network and the Canadian Stroke Network, which have 
recently initiated unique pilot collaboration across the Atlantic 
(Table 3).
Benefits and Added Value
The experience of the European and Canadian Stroke 
Networks has demonstrated that multidisciplinary exper-
tise can provide high levels of complementarity. Pooling of 
resources, mutual training opportunities, and exchange of 
research expertise have served to enhance and accelerate the 
process of translation. Complex issues can be broken down 
and distributed in a coordinated fashion between partners. The 
vast experience of these stroke networks suggests that further 
benefits could be reaped from enhancement of their previously 
developed avenues of collaboration. For example,
1. Stroke research data repositories would collect data 
about results or planned experimental trials and also pro-
duce a catalog of models and methods platforms offered 
by participating centers to the network. In the stroke 
clinical trial area, such repositories already exist, for 
example, at the Cochrane Stroke Group (http://stroke.
cochrane.org/) or the Virtual International Stroke Trials 
Archive (http://www.vista.gla.ac.uk/.) Data contained 
in these repositories have already provided answers to 
many clinical problems.
2. The use of common standards and data elements (such 
as NINDS CDEs for clinical stroke research, http://
www.commondataelements.ninds.nih.gov/Stroke.aspx) 
streamlines research, and allows data sharing.
3. Sharing of biomaterials allows the most effective use of 
precious tissue samples from experimental models and 
organisms.
In addition to these already existing forms of collaboration 
in the stroke field, we propose novel forms of interaction:
1. Participating stroke researchers would consent to certain 
quality standards and common end points and use simi-
lar tests to compare and share results (open labs). This 
would facilitate the free movement of researchers, data 
sharing (including neutral or negative findings), and ex-
change of protocols (including feedback/input on meth-
odological difficulties and solutions).
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2. Laboratories might organize reciprocal audits and data 
monitoring, as well as conduct round robin tests.
3. A network of experimental laboratories could organize 
multicenter trials to replicate key results and perform 
pivotal trials, or conduct randomized phase III type pre-
clinical trials. These examples are neither complete nor 
exclusive; various combinations are possible (eg, multi-
center trial and common data elements, or common data 
elements and data repositories).
4. These multicenter studies would be based on well-
defined study protocols, including robust sample size 
calculations, and would be of sufficient scale to deliver 
the large numbers of animals required to demonstrate 
smaller, but possibly more clinically relevant, treatment 
effects.
5. By allowing experiments with a factorial or stratified de-
sign (including different strains and/or species, different 
severity of injury, different comorbidities) the robustness 
of conclusions of efficacy, and their generalizability, 
could be increased.67
Toward Realization of International, 
Multicenter Preclinical Trials
Bath et al64 and Dirnagl and Fisher65 have called for interna-
tional, multicenter preclinical phase III-type studies before 
moving from stroke models to clinical trials. Such phase III 
preclinical trials would require international participation, 
thus representing structured international collaboration in pre-
clinical stroke research. They are not intended to replace basic 
stroke research targeted at discovering or investigating patho-
physiological mechanisms or drugs (preclinical phase I), or 
initial preclinical trials to demonstrate efficacy by individual 
scientists (preclinical phase II). Rather, they would be based 
on such prior studies, and only those compounds or treatment 
principles that were highly promising in phase I and II would 
move into phase III. Design elements would include steering 
and data monitoring committees, robust and clinically rele-
vant outcome measures, use of biomarkers, sufficient statis-
tical power, prespecified primary efficacy end point, as well 
as hypotheses generating secondary end points, registration in 
public registry (mandatory for publication in scholarly jour-
nals). The complexities of a multicenter multimodal paradigm 
might indeed be a strength of this collaborative format: the 
inclusion of centers with various focal cerebral ischemia mod-
els may be considered to recreate the heterogeneity of stroke 
subtypes and the varying severity of this disorder. Various 
strains (or even species) may be used to mimic patient het-
erogeneity. Studies could be designed in such a way that they 
are informative even when the results are neutral or negative. 
Several international stroke research consortia are currently 
aiming to develop the capacity to undertake international mul-
ticenter animal studies to improve the validity and generaliz-
ability of current preclinical research.
A variation of this format may be deduced from the clinical 
Neurological Emergencies Treatment Trials Network (http://
www.nett.umich.edu/nett) of the NIH/NINDS. It is based on 
the idea that promising new trials of drugs for acute neuro-
logical emergencies that are ready for phase III trials should 
be conducted by sites that have networks of hospitals with 
active emergency departments that can run clinical trials. In 
a similar fashion, principal investigators would submit an 
application for a phase III preclinical trial to a network of 
collaborating laboratories suitably equipped to conduct high-
quality efficacy trials in animals, and the application would 
undergo peer review. Each site could apply to become a center 
Table 3. Examples of Already Existing Large-Scale/Transnational Cooperations in Preclinical Stroke and Stroke-Related Research
European Stroke Network A collaborative effort of the European Union’s Seventh 
Framework Program that brings together researchers, 
government, industry, the nonprofit sector, and patient group 
associations. It coordinates the research efforts of 29 institutions 
in 13 countries
http://www.europeanstrokenetwork.eu
Canadian Stroke Network Established with the help of the Canadian government in 1999. 
It incorporates >100 researchers at 24 universities at present
http://www.canadianstrokenetwork.ca
InTBIR A collaborative effort of the European Commission, the Canadian 
Institutes of Health Research and the National Institutes of 
Health. In July the European Commission 2012 issued a call 
(HEALTH.2013.2.2.1-1) to support InTBIR with ≤30 Mio 
http://ec.europa.eu/research/health/medical- 
research/brain-research/international- 
initiative_en.html
Transatlantic networks-Fondation Leducq Transatlantic Networks of Excellence in Cardiovascular and 
Neurovascular Research. The program awards grants of up to 
US $6 000 000 over 5 years to collaborative teams of European 
and North American scientists, allowing researchers to take 
advantage of the strengths and resources on both sides of the 
Atlantic
http://www.fondationleducq.org
SIRIUS: Sustained Investigation of Recovery and 
Immunologic response after stroke Using  
neural Stem cells
The Department of Neurosurgery of the Stanford University and 
the Translational Center for Regenerative Medicine (University of 
Leipzig) collaborate to assess safety and efficacy parameters of 
allogeneic stem cell therapy for stroke in a large animal species 
before entering a clinical trial. Supported by national funding 
agencies (the California Institute for Regenerative Medicine and 
the German Ministry for Education and Research)
http://www.trm.uni-leipzig.de/en/research/ 
sirius/research-project-sirius/r-sirius-a-1184. 
html
InTBIR indicates International Initiative for Traumatic Brain Injury Research.
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on the basis of their expertise, commitment to high-quality 
and rigorous standards, and unique resources. A review or 
governance committee could decide on the selection of sites 
on the basis of the overall aims, scope, and goals of the pre-
clinical consortium. Positive results that attest to robust effi-
cacy could then be the benchmark for advancing into clinical 
trials. The pharmaceutical industry could be approached to 
support such a network as well and have their treatment plat-
forms deemed appropriate for evaluation by the international 
preclinical network.
Open Issues
True cooperation, as proposed here, raises a number of issues. 
First and foremost, the scientific community (researchers, 
journal editors, scholarly societies) needs to move from reflec-
tion (this article) to action. A bottom-up approach in which 
we share data and consent on quality standards could be the 
beginning. In parallel, international and national funding bod-
ies, such as the European Commission, the NIH, the Canadian 
government, the Australian National Health and Medical 
Research Council, the National Science Foundation of China, 
etc, need to be convinced of the potential value of such col-
laborations. Globalization of the scientific endeavor is pres-
ently a major charge of many of these organizations, and there 
are promising signals that specific programs may be initiated 
in the near future.
Other challenges include intellectual property management, 
development of structures for mutual project governance, 
scientific monitoring, effective dialogue for true multidisci-
plinary involvement beyond neuroscience, and delineation of 
the role of industrial cooperation. Fortunately, however, previ-
ous experience in transnational networks has provided funda-
mental frameworks for addressing such challenges. Another 
concern is authorship of articles generated by the international 
preclinical network. The example of the physics community 
and how it has handled this issue is a valuable lesson.
Conclusions
Translational stroke medicine requires renewal, and inter-
national collaboration in preclinical research may be an 
important step to overcome hurdles impeding progress. The 
tremendous power of international research collaboration 
has been convincingly demonstrated in physics, and several 
transnational collaborations have already delivered proof of 
concept in the stroke field. The experience gleaned from such 
collaborations is paving the way for an exciting new era in 
stroke research, which strives to harness the multitude of ben-
efits achievable through international collaboration. Now is 
the time for concrete action to advance the agenda and estab-
lish an international preclinical stroke network.
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